Aquestive Therapeutics, Inc.
AQST · Nasdaq · United States
Share price · AQST
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when AQST's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 13 Nov 2026+9.5%
Nothing announced by AQST that day or the session before.
- 15 Oct 2026-11.9%
- 26 Aug 2026+6.1%
Nothing announced by AQST that day or the session before.
- 10 Aug 2026+8.9%
- 29 Jun 2026-5.2%
Nothing announced by AQST that day or the session before.
- 25 Jun 2026-10.5%
Nothing announced by AQST that day or the session before.
- 15 May 2026-11.8%
Nothing announced by AQST that day or the session before.
- 14 May 2026+14.5%
- 2 Feb 2026+39.0%
- 9 Jan 2026-37.0%
Share of unusual movement by asset
For each asset, the share of AQST's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | GABA-A receptor (benzodiazepine site)Small molecule | EpilepsyDevelopmental and Epileptic EncephalopathiesLennox-Gastaut Syndrome | |
| Phase 3 | GABA-A receptorSmall molecule | Epilepsy | |
| Preclinical / Unstaged | Alpha- and beta-adrenergic receptors (agonist)Small molecule | Allergic Conditions Anaphylaxis |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(9)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $7.6M | $4.3M | $90M | $17M-$7.0M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $14M | $4.0M | $98M | $23M-$9.4M operating cash flow | report ↗ |
| 2026-Q1 | $14M | $4.2M | $111M | $8.1M-$15M operating cash flow | report ↗ |
| 2025-Q3 | $13M | $4.5M | $129M | $15M-$13M operating cash flow | report ↗ |
| 2025-Q2 | $10M | $4.1M | $61M | $14M-$7.9M operating cash flow | report ↗ |
| 2025-Q1 | $8.7M | $5.4M | $69M | $23M-$23M operating cash flow | report ↗ |
| 2024-Q3 | $14M | $5.3M | $78M | $12M-$12M operating cash flow | report ↗ |
| 2024-Q2 | $20M | $4.2M | $90M | $2.8M-$7.0M operating cash flow | report ↗ |
| 2024-Q1 | $12M | $5.9M | $95M | $13M-$10M operating cash flow | report ↗ |
| 2023-Q3 | $13M | $3.2M | $25M | $2.0M-$2.4M operating cash flow | report ↗ |
| 2023-Q2 | $13M | $3.5M | $22M | $5.8M-$7.9M operating cash flow | report ↗ |
| 2023-Q1 | $11M | $3.5M | $27M | —$8.8M operating cash flow | report ↗ |
| 2022-Q3 | $11M | $3.2M | $19M | $13M$2.8M operating cash flow | report ↗ |
| 2022-Q2 | $13M | $5.2M | $18M | $16M-$6.6M operating cash flow | report ↗ |
| 2022-Q1 | $12M | $4.8M | $15M | $13M-$14M operating cash flow | report ↗ |
| 2021-Q3 | $13M | $4.7M | $31M | $15M-$9.1M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $45M | $17M | $121M | $21M-$52M operating cash flow | report ↗ |
Aquestive reported full-year 2025 revenue of $44.55M, down 22.6% YoY, with R&D spend of $17.19M, down 15.2% YoY. Cash and equivalents stood at $121.17M, and the company reported a net loss of $83.78M, with a quarterly net burn of $83.78M.
The company reaffirmed guidance to resubmit the Anaphylm (dibutepinephrine) sublingual film NDA in Q3 2026 following a Complete Response Letter, with a Type A FDA meeting expected within 30 days, and plans regulatory submissions in Canada and the EU in 2026. FY2026 guidance includes total revenue of $46M to $50M, non-GAAP adjusted EBITDA loss of $35M to $30M, and year-end cash of $70M. AQST-108 Phase 1 dosing was completed with a data readout expected in Q2 2026, and the revenue-sharing agreement with RTW was extended to June 30, 2027.
Insider transactions
Open-market activity, trailing 12 months: 2 purchases ($99K), 17 sales ($2.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-12 | Davis Matthew W. · Chief Development Officer | Open-market sale | 7,197 | $3.55 | $26K | Form 4 |
| 2026-11-10 | Davis Matthew W. · Chief Development Officer | Tax withholding | 5,303 | $3.52 | $19K | Form 4 |
| 2026-11-10 | Daly Richard J · director | Open-market purchase | 1,200 | $3.53 | $4K | Form 4 |
| 2026-11-10 | Daly Richard J · director | Open-market purchase | 26,825 | $3.54 | $95K | Form 4 |
| 2026-11-06 | Daly Richard J · director | Award / grant (derivative) | 57,000 | — | — | Form 4 |
| 2026-10-21 | Cochran John · director | Other (see filing) | 62,229 | — | — | Form 4 |
| 2026-10-15 | Barber Daniel · director, President and CEO | Open-market sale | 25,000 | $4.22 | $106K | Form 4 |
| 2026-09-15 | Barber Daniel · director, President and CEO | Open-market sale | 25,000 | $4.82 | $120K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 178 reporting institutions held 71.8M shares ($293.1M, 57.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Bratton Capital Management, L.P. | 9,810,958 | $40.7M |
| 2 | BlackRock, Inc. | 7,509,071 | $31.2M |
| 3 | RTW INVESTMENTS, LP | 7,426,471 | $30.8M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 4,443,698 | $18.4M |
| 5 | FEDERATED HERMES, INC. | 2,940,339 | $12.2M |
| 6 | Balyasny Asset Management L.P. | 2,900,570 | $12.0M |
| 7 | STATE STREET CORP | 2,546,191 | $10.6M |
| 8 | SAMSARA BIOCAPITAL, LLC | 2,500,000 | $10.4M |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 2,408,191 | $10.0M |
| 10 | BANK OF AMERICA CORP /DE/ | 2,405,050 | $10.0M |
| 11 | Sio Capital Management, LLC | 1,922,887 | $8.0M |
| 12 | MORGAN STANLEY | 1,591,792 | $6.6M |
| 13 | Blue Owl Capital Holdings LP | 1,347,932 | $5.6M |
| 14 | TWO SIGMA INVESTMENTS, LP | 1,139,404 | $4.7M |
| 15 | COMMONWEALTH EQUITY SERVICES, LLC | 1,082,680 | $4.5M |